FDA clears DermaSensor AI-powered skin cancer detection device
January 17, 2024
DermaSensor announced today that the FDA cleared its real-time, non-invasive, AI-powered skin cancer evaluation system.
DermaSensor announced today that the FDA cleared its real-time, non-invasive, AI-powered skin cancer evaluation system.
Limited Market Release of First Purpose-Built OR Product to Begin in First Half of 2024
Zeiss Medical Technology announced that the FDA approved the VisuMax 800 with Smile Pro software.
Neuralace Medical announced today that it received FDA clearance for its chronic painful diabetic neuropathy (PDN) treatment.
Zeta Surgical announced today that the FDA granted it a special 510(k) clearance for expanded software functionality.
3Spine’s MOTUS device is a ‘first-of-kind’ breakthrough medical technology indicated for the biomechanical reconstruction and stabilization of a spinal motion segment
SCHAFFHAUSEN, CH / ACCESSWIRE / January 8, 2024 / Occlutech Holding AG Occlutech ASD Occluder delivers positive procedural outcomes with strong efficacy and a low rate of complications[i]
SimBioSys announced that it received FDA 510(k) clearance for its TumorSight cloud-based digital precision medicine platform.
Butterfly Network (NYSE:BFLY) announced today that it received FDA clearance for its next-generation handheld ultrasound system.
Medtronic (NYSE: MDT)+
today announced FDA approval of its Percept RC deep brain stimulation system, the latest member of its Percept line of DBS devices.